| DRUG | SUPPLIED | DOSE | COMMENTS |
|---|---|---|---|
| OSELTAMIVIR (Paeds) (Tamiflu) Mechanism of action: Antiviral; neuraminidase inhibitor Ref: 6, 44, 67, 112, 628 Last update: 2022-07-28 |
Capsule: 75 mg, 30 mg, 45 mg, 75mg Suspension: 6 mg/mL (commercially available) |
Anti-viral treatment Children: < 12 months: 3 mg/kg/dose PO BID x 5 days >=12 months to <13 years: (weight based) <= 15 kg: 30 mg/dose PO BID x 5 days Adolescents >= 13 years and adults: 75 mg/dose PO BID x 5 days Patients with GFR <30 mL/min: Once daily x 5 days Patients on PD/HD: Give single dose per above dosing, then consult pharmacist for post dialysis re-dose |
Indicated for patients who are moderately or severely ill with influenza-like illness or at high risk for influenza related complications (cardiac or pulmonary disorder, diabetes and other metabolic diseases, cancer, immunodeficiency/ immunosuppression, renal disease, anemia or hemoglobinopathy, children <2 years of age). Refer to "BCCH oseltamivir algorithm" on PHSA SHOP Greatest benefit is when oseltamivir is started within 48 hrs of influenza illness onset, but may still be beneficial when administered >48 hrs. Pre-exposure and post-exposure prophylaxis is currently not recommended except in limited cases. Dose adjustment required in patients with renal impairment (GFR <30 mL/min or dialysis). Nausea and vomiting may be less severe if taken with food. Transient neuropsychiatric events (self-injury, delirium) have been reported in postmarketing surveillance, with the majority in pediatric populations. Monitor for abnormal behaviors. Capsules can be opened and mixed with sweetened liquids (chocolate syrup) or juice immediately prior to administration. Standard Prescription: oseltamivir__mg PO Q__H x__days |